No Prescription |
 |
 | ||
|
Ovestin Vaginal Cream Generic Oestriol |
|
| ||
No Prescription » Prescription Drugs 12 » Ovestin Vaginal Cream Generic Oestriol Indications:Atrophy of the lower urogenital tract related to oestrogen deficiency notably1.For the treatment of vaginal complaints such as dyspareunia dryness and itching. for the prevention of recurrent infections of the vagina and lower urinary tract. 2.In the management of micturition complaints (such as frequency and dysuria) and mild urinary incontinence. Pre- and postoperative therapy in postmenopausal women undergoing vaginal surgery.3.Climacteric complaints such as hot flushes and night sweating.4.A diagnostic aid in case of a doubtful atrophic cervical smear.5.Infertility due to cervical hostility.Dosage And Administration:Dosage:Atrophy of the lower urogenital tract 1 application per day for the first weeks followed by a gradual reduction based on relief of symptoms until a maintenance dosage (e.g. 1 application twice a week) is reached. Pre- and post-operative therapy in postmenopausal women undergoing vaginal surgery1 application per day in the 2 weeks before surgery; 1 application twice a week in the 2 weeks after surgery.A diagnostic aid in case of a doubtful atrophic cervical smear1 application on alternate days in the week before taking the next smear.AdministrationOVESTIN cream should be administered intravaginally by means of a calibrated applicator before retiring at night.One application (applicator filled to the red mark) contains 0.5g OVESTIN cream which corresponds to 0.5mg oestriol.Instructions For Use For The PatientRemove cap from the tube invert it and use the sharp point to open the tube. Screw the end of the applicator onto the tube. Squeeze tube to fill the applicator with the cream until the plunger stops. Unscrew applicator from tube and replace cap on tube. To apply cream lie down insert end of applicator deep into the vagina. Slowly push plunger all the way in until applicator is empty. After use pull plunger out of barrel and wash both in warm soapy water. Do not use detergents. Rinse well afterwards.DO NOT PUT THE APPLICATOR IN HOT OR BOILING WATER.A missed dose should be administered as soon as remembered unless the missed dose is noticed at the day of the next dose. In the latter case the missed dose should be skipped and the regular dosing scheme continued. Two doses must never be administered on the same day.For initiation and continuation of treatment of postmenopausal symptoms the lowest effective dose for the shortest duration of time should be used (see Warnings and Precautions).In women not taking HRT or women who switch from a continuous combined HRT product treatment with OVESTIN may be started on any day. Women who switch from cyclic HRT regimen should start OVESTIN treatment one week after completion of the cycle. Buy Ovestin Vaginal Cream Generic Oestriol and other Prescription Drugs 12 products online at Medstore. Buy Online at Medstore - Click Here!
About Ovestin Vaginal Cream Generic Oestriol: Product Type: Prescription Drugs 12 Ovestin Vaginal Cream ( Generic Oestriol ) Ovestin Vaginal Cream (Generic Oestriol) Generic Oestriol 1mg/gm Generic Oestriol Ovestin Vaginal Cream
View more Prescription Drugs 12 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
